Abstract
We report a case of acute hepatitis of autoimmune origin which occurred in a 43-yr-old woman during iv glucocorticoid (GC) pulse therapy for Graves’ ophthalmopathy (GO). Prior to therapy, liver function tests were normal with no previous history of liver disorders or conditions predisposing to GC-associated liver damage. After the administration of a 4.7-g cumulative dose of methylprednisolone acetate, there was a marked increase of liver enzymes, prompting immediate discontinuation of iv GC. Nevertheless, liver enzymes increased further, reaching a peak 45 days later, with values 30- to 50-fold greater than those prior to therapy, associated with evidence of impaired liver function. Liver biopsy showed a marked lymphocytic infiltration, likely indicating an autoimmune hepatitis. Based on the assumption that following GC-induced immune suppression, autoimmune hepatitis might have been precipitated by sudden re-activation of the immune system during interpulse periods, we treated the patient with im and then oral GC, in order to re-induce immune suppression. Within three days from re-institution of GC therapy, there was a marked reduction of liver enzymes and amelioration of liver function. Complete normalization was achieved two months later, while the patient was still receiving a low maintenance dose of oral prednisone.
Similar content being viewed by others
References
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.
Bartalena L, Marcocci C, Tanda ML, et al. Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 2002, 12: 245–52.
Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoid associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endoc Metab 2001, 86: 3562–7.
Marcocci C, Marino M, Rocchi R, Menconi F, Morabito E, Pinchera A. Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 272–80.
Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A. Orbital radiotherapy for Graves’ ophthalmopathy: useful or useless? Safe or dangerous? J Endocrinol Invest 2003, 26: 5–16.
Weissel M, Hauff W. Fatal acute liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000, 10: 521.
Dourakis SP, Sevastianos VA, Kalipi P. Acute severe steathoepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97: 1074–5.
Nanki T, Koike R, Miyasaka N. Subacute severe steathoepatitis during prednisolone therapy for systemic lupus erythematosus. Am J Gastroenterol 1999, 94: 3379.
Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 2004, 14: 403–6.
Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003, 7: 435–51.
Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto’s thyroiditis: case report. Thyroid 2004, 14: 631–4.
Pinchera A, Wiersinga W, Glinoer D. Classification of eye changes in Graves’ disease. Thyroid 1992, 2: 235–6.
Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002, 13: 293–303.
Obermayer-Straub P, Strassberg CC, Manns MP. Autoimmune hepatitis. J Hepatol 2000, 32: 181–97.
Lesnicar GA. prospective study of viral hepatitis A and the question of chronicity. Hepatogastroenterology 1988, 35: 69–72.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marinò, M., Morabito, E., Altea, M.A. et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 28, 280–284 (2005). https://doi.org/10.1007/BF03345386
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345386